



Zim Laboratories Limited

Registered Office : Sadoday Gyan(Ground Floor),Opp.NADT,Nelson Square Nagpur - 440013, Maharashtra, India
CIN:U99999MH1984PLC032172, Website: www.zimlab.in

STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2018

Sr. no.	Particulars	Quarter ended			Year ended	Year ended
		31-03.2018 (Unaudited)	31.12.2017 (Unaudited)	31-03.2017 (Unaudited)	31-03.2018 (Audited)	31-03.2017 (Audited)
1	Income					
	a) Revenue from operations	7,063.11	7,505.90	7,200.27	27,336.38	24,095.91
	b) Other income	157.84	25.99	339.68	342.24	485.49
	Total income	7,220.95	7,531.89	7,539.95	27,678.62	24,581.40
2	Expenses					
	a) Cost of materials consumed	3,320.59	3,578.95	2,302.55	12,400.42	9,340.36
	b) Purchases of stock-in-trade	236.78	388.90	1,337.72	1,778.64	2,515.11
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	366.12	(185.77)	155.55	(90.10)	141.36
	d) Excise duty (refer note 7)	-	-	195.92	146.54	594.60
	e) Employee benefits	1,143.56	1,019.61	842.63	4,080.35	3,299.86
	f) Finance costs	293.82	150.97	92.92	934.39	981.89
	g) Depreciation and amortisation	261.33	251.70	225.79	978.95	902.25
	h) Other expenses	1,170.19	1,612.48	1,465.09	5,624.37	5,048.04
	Total expenses	6,792.39	6,816.84	6,618.17	25,853.56	22,823.47
3	Profit before exceptional item and tax (1-2)	428.56	715.05	921.78	1,825.06	1,757.93
4	Exceptional Items	586.30	-	-	586.30	-
	Profit before tax (3+4)	1,014.86	715.05	921.78	2,411.36	1,757.93
5	Tax expense					
	Current Tax	(199.75)	16.07	258.90	(125.62)	365.45
	Deferred Tax	520.00	71.08	(482.65)	708.20	(474.19)
5	Total tax expense / (benefit)	320.25	87.15	(223.75)	582.58	(108.74)
6	Profit after tax (4-5)	694.61	627.90	1,145.53	1,828.78	1,866.67
7	Other comprehensive income					
	a) Items that will not be reclassified to profit or loss	5.52	(8.15)	(8.14)	(18.92)	(32.58)
	b) Tax expense/(benefit) on the items that will not be reclassified to profit or loss	(1.91)	2.82	2.82	6.55	11.28
	Other comprehensive income (net of tax)	3.61	(5.33)	(5.32)	(12.37)	(21.30)
7	Total comprehensive income (6+7)	698.22	622.57	1,140.21	1,816.41	1,845.37
8	Paid-up equity share capital	805.98	805.98	802.91	805.98	802.91
9	Earnings per share (face value of ₹ 10/- each) (not annualised) (₹)					
	Basic	8.60	7.79	14.26	22.72	23.27
	Diluted	8.54	7.74	14.11	22.56	23.03



Notes:

- 1) This result were reviewed by the Audit Committee and were thereafter approved by the Board of Directors of the Company at their respective meetings held on 25 May 2018.
- 2) The financial results for the quarter and year ended 31 March 2018 and for the quarter ended 31 December 2017 are in compliance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind As) notified by the Ministry of Corporate Affairs. Consequently, the financial results for the corresponding quarter and year ended 31 March 2017 have been restated to comply with Ind AS to make them comparable.
- 3) The Company has received notice from BSE Limited (BSE) whereby the Company has been provided with an option to either complete the procedures for direct listing of its equity shares on nationwide stock exchange or provide exit to public shareholders by acquiring their equity shares at rates determined by independent valuer. Pursuant to receipt of such notice, the Company has initiated the procedures for direct listing of its equity shares on BSE.
- 4) The Company has adopted Ind AS notified by the Ministry of Corporate Affairs with effect from 01 April 2017 and accordingly these financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 Interim Financial Reporting prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder. The date of transition is 01 April 2016. The impact of transition has been accounted in the retained earnings as at 01 April 2016 and accordingly, the comparative period results for the quarter and year ended 31 March 2017 have been restated.


In the view of various clarifications being issued by the Ind AS transition facilitation group (ITFG) constituted by the Accounting Standard Board of the Institute of Chartered Accountants of India, it may be possible that the interim financials may undergo adjustments on finalisation of the full year Ind AS financial statements as at and for the year ending 31 March 2018 due to treatments/method suggested by ITFG on application of Ind AS.


- 5) Reconciliation of Net profit under previous GAAP and the Total Comprehensive Income as per Ind AS for the quarter and year ended 31 March 2017 is as per the table below:

Particulars	₹ in Lakhs	
	Quarter ended 31.03.2017	Year ended 31.03.2017
Net profit after tax for the period under erstwhile Indian GAAP	1,143.32	1,859.89
Impact of recognising actuarial gains / losses in OCI	8.14	32.58
Loan processing charges recognised	(3.72)	(14.86)
Others	0.61	0.34
Impact of deferred taxes on the above adjustments	(2.82)	(11.28)
Net profit after tax for the period under Ind AS	1,145.53	1,866.67
Other comprehensive income (net of tax)	(5.32)	(21.30)
Total comprehensive income	1,140.21	1,845.37

- 6) The Company is principally engaged in single business segment which is "pharmaceuticals".
- 7) Excise duty on sales was included under Revenue from operations and disclosed separately under Expenses upto all reporting period ended 30 June 2017. Post implementation of Goods and Service tax (GST) with effect from 01 July 2017, revenue from operations is reported net of GST and hence to that extent results are not comparable.

For and on behalf of the board of directors of Zim Laboratories Limited


Anwar S. Daud
Managing Director


Zulfiqar M. Kamal
Director & CFO

Place: Nagpur
Date: 25 May 2018

